XCNQASIA
Market cap378kUSD
Feb 06, Last price
0.02CAD
Name
Asia Green Biotechnology Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-221k
L+11.53%
CFO
-36k
L-72.21%
Profile
Asia Green Biotechnology Corp., an early stage international bio-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology in Asia. The company focuses on planting, growing, and harvesting new and valuable strains of hemp and related crops. It has an agreement with Pathway Rx Inc. and PNW Biosciences Inc. for the clinical development and commercialization of the cannabis sativa varieties for prevention and treatment of COVID-19 and other infectious diseases. The company was formerly known as Asia Cannabis Corp. and changed its name to Asia Green Biotechnology Corp. in April 2020. Asia Green Biotechnology Corp. was incorporated in 2017 and is based in Calgary, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 145 | 158 | 458 | |||
Unusual Expense (Income) | ||||||
NOPBT | (145) | (158) | (458) | |||
NOPBT Margin | ||||||
Operating Taxes | 1 | |||||
Tax Rate | ||||||
NOPAT | (145) | (158) | (460) | |||
Net income | (221) 11.53% | (198) -62.28% | (526) -4.89% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 237 | 150 | ||||
Long-term debt | 75 | 150 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | 236 | 213 | 83 | |||
| Cash flow | ||||||
Cash from operating activities | (36) | (130) | (464) | |||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | 25 | 75 | 150 | |||
FCF | (34) | (102) | (434) | |||
| Balance | ||||||
Cash | 1 | 12 | 67 | |||
Long term investments | ||||||
Excess cash | 1 | 12 | 67 | |||
Stockholders' equity | (1,413) | (1,226) | (1,028) | |||
Invested Capital | 1,189 | 1,176 | 1,101 | |||
ROIC | ||||||
ROCE | 64.45% | 314.91% | ||||
| EV | ||||||
Common stock shares outstanding | 36,247 | 36,106 | 34,004 | |||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (145) | (158) | (458) | |||
EV/EBITDA | ||||||
Interest | 19 | 1 | ||||
Interest/NOPBT | ||||||